ArticleClinical and experimental medicine2025
From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChimeric antigen receptor (CAR) based therapies are promising in systemic autoimmune rheumatic disease (SARD) according to recent case reports. To establish the state of the art of the applications of CAR therapies in rheumatology, PubMed, EMBASE, Lilacs, as well as clinical trial registries were searched. Any type of original article that reported the use of these therapies in patients with SARD was included. Forty-eight studies were included from databases. Ninety-five ongoing trials were included from clinical trials registries. The most used type of CAR was a CAR-T against CD19, showing good preliminary results. Other targets used were BCMA, PD-1, a modified HLA and citrullinated peptides among others. The use of other cell types such as natural killer and regulatory T cells was also found. CAR-based therapies in rheumatology are in an early stage of development but with promising results. There has been a notable growth in human patients treated with this intervention in the last 2 years. This and other innovative designs will offer a wide range of new therapeutic possibilities. Results of ongoing clinical trials are needed to establish their efficacy and safety in SARD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.